Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenBisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsImmune regulation of bone metastasisFCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.Bone-immune cell crosstalk: bone diseases.Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.Clinical nomogram to predict bone-only metastasis in patients with early breast carcinomaRadiotherapy, Bisphosphonates and Surgical Stabilization of Complete or Impending Pathologic Fractures in Patients with Metastatic Bone DiseaseToll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.Patient pathway for breast cancer: turning points and future aspirations.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
P2860
Q26746212-704F2D97-A2B7-4CC9-A166-8DDE4F78ADEBQ26749972-E8C80EAA-67E4-432E-9E58-2A32DF4C3049Q26861586-0901B67E-E1EF-4203-967C-49F36598F2FDQ27005871-24CE0ADC-8680-4F6C-B730-8A9467F86443Q34088194-45808BCE-AB93-47F9-83DC-C22C35FC7817Q35592362-1790C797-2503-4521-8B0E-8C6906E9A505Q35934290-507552BE-8C8E-4A6B-83FF-580B055948C4Q36295018-3A40EF12-6D99-4540-A3AF-D2F724BBBC8EQ36372417-653C8D60-8EB3-4F75-8849-09154DBEF94CQ37699431-E7719211-BB0F-41DA-B1DD-8203E1BFE5D4Q38389148-7A736736-0C8E-4936-AEBF-B1DA5860473CQ40468319-B0808207-F282-4866-9587-A8C21B9CC67BQ40554954-BDEEC61B-785C-4816-80A1-0049B8B37ADAQ41120073-4084209B-8419-4FC3-A71C-9939962B3357Q41595578-A96E53D7-C096-41CA-B068-50F22537E221Q42363605-B295753F-37E5-4750-AE11-2141127678FF
P2860
Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@en
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@nl
type
label
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@en
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@nl
prefLabel
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@en
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@nl
P2093
P2860
P31
P921
P356
P1476
Adjuvant zoledronic acid thera ...... atic review and meta-analysis.
@en
P2093
Mingfeng He
Weidong Fan
Xianquan Zhang
P2860
P2888
P356
10.1186/1756-8722-6-80
P5008
P577
2013-10-23T00:00:00Z
P5875
P6179
1013938436